This article first appeared on GuruFocus.
Cathie Wood’s Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (NASDAQ:TSLA) and Rocket Lab (NASDAQ:RKLB).
Selling activity focused on electric vehicles and cloud software. Ark reduced 60,715 Tesla (NASDAQ:TSLA) shares across ARKK, ARKW (ARKW), and ARKQ ETFs, representing roughly $30 million in total.
Ark’s funds added roughly 155,649 shares of CRISPR Therapeutics (CRSP), boosting exposure to the Swiss-American biotech focused on gene-based therapies using CRISPR/Cas9 technology. Pacific Biosciences of California (PACB) also saw a combined purchase of about 1.13 million shares across ARKK (ARKK) and ARKG (ARKG) ETFs. Smaller additions included Beam Therapeutics (NASDAQ:BEAM) and Twist Bioscience (TWST).
In autonomous mobility, ARKQ (ARKQ) acquired approximately 979,000 shares of robotaxi developer WeRide (WRD). Space-focused ARKX added around 447,000 shares of Archer Aviation (NYSE:ACHR) and 19,248 shares of AeroVironment (AVAV). Ark also purchased about 107,000 shares of Oklo (NYSE:OKLO), a U.S. nuclear microreactor company targeting AI and defense computing applications.